Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK
Aim To examine preferences for oral medication attributes among participants with early and advanced type 2 diabetes mellitus (T2DM) in the UK using a discrete choice experiment (DCE). Methods A web‐based DCE was administered where participants indicated which medication they preferred from two diff...
Gespeichert in:
| Veröffentlicht in: | Diabetes, obesity & metabolism obesity & metabolism, 2013-09, Vol.15 (9), p.802-809 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 809 |
|---|---|
| container_issue | 9 |
| container_start_page | 802 |
| container_title | Diabetes, obesity & metabolism |
| container_volume | 15 |
| creator | Gelhorn, H. L. Stringer, S. M. Brooks, A. Thompson, C. Monz, B. U. Boye, K. S. Hach, T. Lund, S. S. Palencia, R. |
| description | Aim
To examine preferences for oral medication attributes among participants with early and advanced type 2 diabetes mellitus (T2DM) in the UK using a discrete choice experiment (DCE).
Methods
A web‐based DCE was administered where participants indicated which medication they preferred from two different hypothetical oral anti‐diabetic (OAD) medication profiles, each composed of differing levels of seven attributes (efficacy, hypoglycaemic events, weight change, gastrointestinal/nausea side effects, urinary tract infection and genital infection, blood pressure and cardiovascular risk) for 20 sets of pair‐wise comparisons. A random effects multinomial logit regression model was used to estimate the preference weight (PW) for each of the attribute levels, and the relative importance (RI) of each attribute was calculated. Analyses were conducted for the overall sample and for medication and gender subgroups.
Results
The final sample included 100 participants with a mean age of 62.9 (SD 11.1) years and comparable numbers of participants of each gender (51% male, 49% female). The majority of the participants were White‐British (92%). The total PW and corresponding RI were highest for four of the seven attributes: hypoglycaemic events (PW = 1.98; RI = 24.7%), weight change (PW = 1.65; RI = 20.6%), gastrointestinal/nausea side effects (PW = 1.49; RI = 18.6%) and efficacy (PW = 1.44; RI = 18.0%). The RI values differed for some attributes across gender and number of current T2DM medication subgroups.
Conclusion
The results suggest that hypoglycaemia, weight change, gastrointestinal side effects and efficacy are of primary importance to patients in their OAD preferences in T2DM. These four attributes comprised over 80% of the RI. |
| doi_str_mv | 10.1111/dom.12091 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1427002930</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3027474991</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4521-864be39e1d753977117bd41f93fe5c23483054709377e737d6ef8359f9c9d1193</originalsourceid><addsrcrecordid>eNqNkV1rFTEQhoMotlYv_AMS8EYvts3kY7O5lNpWsZ_QIogQ9mPWpp7dPU2y1PPvnfa0vRAUc5Mw88zLm3kZew1iG-jsdNOwDVI4eMI2QZeqACXLp3dvWVROyA32IqUrIYRWlX3ONqTSJfXUJvt-GrHHiGOLifdT5AN2oa1zmEZe5xxDM2fq1MM0_uBLquOYE78J-ZLn1RK55F2oG7xlBlwsQp4TDyPPl8gvvrxkz_p6kfDV_b3FLvb3znc_FYcnB593PxwWrTYSiqrUDSqH0FmjnLUAtuk09E71aFryWilhtBVOWYtW2a7EvlLG9a51HYBTW-zdWncZp-sZU_ZDSC3ZqUec5uRBSyuEdEr8BwqmFM5JS-jbP9CraY4jfcSTH6fBKiH-RZEWkJIBQ9T7NdXGKSVauV_GMNRx5UH42ww9ZejvMiT2zb3i3FAaj-RDaATsrIGbsMDV35X8x5OjB8liPRFSxl-PE3X86UtaqPFfjw_86fnZ2b75ZrxRvwGvBrEu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1411992515</pqid></control><display><type>article</type><title>Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Gelhorn, H. L. ; Stringer, S. M. ; Brooks, A. ; Thompson, C. ; Monz, B. U. ; Boye, K. S. ; Hach, T. ; Lund, S. S. ; Palencia, R.</creator><creatorcontrib>Gelhorn, H. L. ; Stringer, S. M. ; Brooks, A. ; Thompson, C. ; Monz, B. U. ; Boye, K. S. ; Hach, T. ; Lund, S. S. ; Palencia, R.</creatorcontrib><description>Aim
To examine preferences for oral medication attributes among participants with early and advanced type 2 diabetes mellitus (T2DM) in the UK using a discrete choice experiment (DCE).
Methods
A web‐based DCE was administered where participants indicated which medication they preferred from two different hypothetical oral anti‐diabetic (OAD) medication profiles, each composed of differing levels of seven attributes (efficacy, hypoglycaemic events, weight change, gastrointestinal/nausea side effects, urinary tract infection and genital infection, blood pressure and cardiovascular risk) for 20 sets of pair‐wise comparisons. A random effects multinomial logit regression model was used to estimate the preference weight (PW) for each of the attribute levels, and the relative importance (RI) of each attribute was calculated. Analyses were conducted for the overall sample and for medication and gender subgroups.
Results
The final sample included 100 participants with a mean age of 62.9 (SD 11.1) years and comparable numbers of participants of each gender (51% male, 49% female). The majority of the participants were White‐British (92%). The total PW and corresponding RI were highest for four of the seven attributes: hypoglycaemic events (PW = 1.98; RI = 24.7%), weight change (PW = 1.65; RI = 20.6%), gastrointestinal/nausea side effects (PW = 1.49; RI = 18.6%) and efficacy (PW = 1.44; RI = 18.0%). The RI values differed for some attributes across gender and number of current T2DM medication subgroups.
Conclusion
The results suggest that hypoglycaemia, weight change, gastrointestinal side effects and efficacy are of primary importance to patients in their OAD preferences in T2DM. These four attributes comprised over 80% of the RI.</description><identifier>ISSN: 1462-8902</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/dom.12091</identifier><identifier>PMID: 23464623</identifier><identifier>CODEN: DOMEF6</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Administration, Oral ; Adult ; Blood pressure ; Cardiovascular diseases ; Cardiovascular Diseases - chemically induced ; Cardiovascular Diseases - psychology ; Choice Behavior ; Decision Making ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - psychology ; discrete choice experiment ; Female ; Gastrointestinal Diseases - chemically induced ; Gastrointestinal Diseases - psychology ; Gender ; Humans ; Hypoglycemia ; Hypoglycemia - chemically induced ; Hypoglycemia - psychology ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - therapeutic use ; Internet ; Logistic Models ; Male ; Medical research ; Medication Adherence ; Middle Aged ; Nausea ; Patient Preference ; Pilot Projects ; Risk Factors ; Side effects ; Studies ; Surveys and Questionnaires ; type 2 diabetes ; United Kingdom - epidemiology ; Urinary tract ; Weight ; Weight Gain - drug effects ; Weight Loss - drug effects</subject><ispartof>Diabetes, obesity & metabolism, 2013-09, Vol.15 (9), p.802-809</ispartof><rights>2013 Blackwell Publishing Ltd</rights><rights>2013 Blackwell Publishing Ltd.</rights><rights>2013 John Wiley & Sons Ltd</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4521-864be39e1d753977117bd41f93fe5c23483054709377e737d6ef8359f9c9d1193</citedby><cites>FETCH-LOGICAL-c4521-864be39e1d753977117bd41f93fe5c23483054709377e737d6ef8359f9c9d1193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdom.12091$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdom.12091$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23464623$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gelhorn, H. L.</creatorcontrib><creatorcontrib>Stringer, S. M.</creatorcontrib><creatorcontrib>Brooks, A.</creatorcontrib><creatorcontrib>Thompson, C.</creatorcontrib><creatorcontrib>Monz, B. U.</creatorcontrib><creatorcontrib>Boye, K. S.</creatorcontrib><creatorcontrib>Hach, T.</creatorcontrib><creatorcontrib>Lund, S. S.</creatorcontrib><creatorcontrib>Palencia, R.</creatorcontrib><title>Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK</title><title>Diabetes, obesity & metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description>Aim
To examine preferences for oral medication attributes among participants with early and advanced type 2 diabetes mellitus (T2DM) in the UK using a discrete choice experiment (DCE).
Methods
A web‐based DCE was administered where participants indicated which medication they preferred from two different hypothetical oral anti‐diabetic (OAD) medication profiles, each composed of differing levels of seven attributes (efficacy, hypoglycaemic events, weight change, gastrointestinal/nausea side effects, urinary tract infection and genital infection, blood pressure and cardiovascular risk) for 20 sets of pair‐wise comparisons. A random effects multinomial logit regression model was used to estimate the preference weight (PW) for each of the attribute levels, and the relative importance (RI) of each attribute was calculated. Analyses were conducted for the overall sample and for medication and gender subgroups.
Results
The final sample included 100 participants with a mean age of 62.9 (SD 11.1) years and comparable numbers of participants of each gender (51% male, 49% female). The majority of the participants were White‐British (92%). The total PW and corresponding RI were highest for four of the seven attributes: hypoglycaemic events (PW = 1.98; RI = 24.7%), weight change (PW = 1.65; RI = 20.6%), gastrointestinal/nausea side effects (PW = 1.49; RI = 18.6%) and efficacy (PW = 1.44; RI = 18.0%). The RI values differed for some attributes across gender and number of current T2DM medication subgroups.
Conclusion
The results suggest that hypoglycaemia, weight change, gastrointestinal side effects and efficacy are of primary importance to patients in their OAD preferences in T2DM. These four attributes comprised over 80% of the RI.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Blood pressure</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - chemically induced</subject><subject>Cardiovascular Diseases - psychology</subject><subject>Choice Behavior</subject><subject>Decision Making</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - psychology</subject><subject>discrete choice experiment</subject><subject>Female</subject><subject>Gastrointestinal Diseases - chemically induced</subject><subject>Gastrointestinal Diseases - psychology</subject><subject>Gender</subject><subject>Humans</subject><subject>Hypoglycemia</subject><subject>Hypoglycemia - chemically induced</subject><subject>Hypoglycemia - psychology</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Internet</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Medical research</subject><subject>Medication Adherence</subject><subject>Middle Aged</subject><subject>Nausea</subject><subject>Patient Preference</subject><subject>Pilot Projects</subject><subject>Risk Factors</subject><subject>Side effects</subject><subject>Studies</subject><subject>Surveys and Questionnaires</subject><subject>type 2 diabetes</subject><subject>United Kingdom - epidemiology</subject><subject>Urinary tract</subject><subject>Weight</subject><subject>Weight Gain - drug effects</subject><subject>Weight Loss - drug effects</subject><issn>1462-8902</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkV1rFTEQhoMotlYv_AMS8EYvts3kY7O5lNpWsZ_QIogQ9mPWpp7dPU2y1PPvnfa0vRAUc5Mw88zLm3kZew1iG-jsdNOwDVI4eMI2QZeqACXLp3dvWVROyA32IqUrIYRWlX3ONqTSJfXUJvt-GrHHiGOLifdT5AN2oa1zmEZe5xxDM2fq1MM0_uBLquOYE78J-ZLn1RK55F2oG7xlBlwsQp4TDyPPl8gvvrxkz_p6kfDV_b3FLvb3znc_FYcnB593PxwWrTYSiqrUDSqH0FmjnLUAtuk09E71aFryWilhtBVOWYtW2a7EvlLG9a51HYBTW-zdWncZp-sZU_ZDSC3ZqUec5uRBSyuEdEr8BwqmFM5JS-jbP9CraY4jfcSTH6fBKiH-RZEWkJIBQ9T7NdXGKSVauV_GMNRx5UH42ww9ZejvMiT2zb3i3FAaj-RDaATsrIGbsMDV35X8x5OjB8liPRFSxl-PE3X86UtaqPFfjw_86fnZ2b75ZrxRvwGvBrEu</recordid><startdate>201309</startdate><enddate>201309</enddate><creator>Gelhorn, H. L.</creator><creator>Stringer, S. M.</creator><creator>Brooks, A.</creator><creator>Thompson, C.</creator><creator>Monz, B. U.</creator><creator>Boye, K. S.</creator><creator>Hach, T.</creator><creator>Lund, S. S.</creator><creator>Palencia, R.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>7U1</scope><scope>7U2</scope><scope>C1K</scope></search><sort><creationdate>201309</creationdate><title>Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK</title><author>Gelhorn, H. L. ; Stringer, S. M. ; Brooks, A. ; Thompson, C. ; Monz, B. U. ; Boye, K. S. ; Hach, T. ; Lund, S. S. ; Palencia, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4521-864be39e1d753977117bd41f93fe5c23483054709377e737d6ef8359f9c9d1193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Blood pressure</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - chemically induced</topic><topic>Cardiovascular Diseases - psychology</topic><topic>Choice Behavior</topic><topic>Decision Making</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - psychology</topic><topic>discrete choice experiment</topic><topic>Female</topic><topic>Gastrointestinal Diseases - chemically induced</topic><topic>Gastrointestinal Diseases - psychology</topic><topic>Gender</topic><topic>Humans</topic><topic>Hypoglycemia</topic><topic>Hypoglycemia - chemically induced</topic><topic>Hypoglycemia - psychology</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Internet</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Medical research</topic><topic>Medication Adherence</topic><topic>Middle Aged</topic><topic>Nausea</topic><topic>Patient Preference</topic><topic>Pilot Projects</topic><topic>Risk Factors</topic><topic>Side effects</topic><topic>Studies</topic><topic>Surveys and Questionnaires</topic><topic>type 2 diabetes</topic><topic>United Kingdom - epidemiology</topic><topic>Urinary tract</topic><topic>Weight</topic><topic>Weight Gain - drug effects</topic><topic>Weight Loss - drug effects</topic><toplevel>online_resources</toplevel><creatorcontrib>Gelhorn, H. L.</creatorcontrib><creatorcontrib>Stringer, S. M.</creatorcontrib><creatorcontrib>Brooks, A.</creatorcontrib><creatorcontrib>Thompson, C.</creatorcontrib><creatorcontrib>Monz, B. U.</creatorcontrib><creatorcontrib>Boye, K. S.</creatorcontrib><creatorcontrib>Hach, T.</creatorcontrib><creatorcontrib>Lund, S. S.</creatorcontrib><creatorcontrib>Palencia, R.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Diabetes, obesity & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gelhorn, H. L.</au><au>Stringer, S. M.</au><au>Brooks, A.</au><au>Thompson, C.</au><au>Monz, B. U.</au><au>Boye, K. S.</au><au>Hach, T.</au><au>Lund, S. S.</au><au>Palencia, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK</atitle><jtitle>Diabetes, obesity & metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2013-09</date><risdate>2013</risdate><volume>15</volume><issue>9</issue><spage>802</spage><epage>809</epage><pages>802-809</pages><issn>1462-8902</issn><eissn>1463-1326</eissn><coden>DOMEF6</coden><abstract>Aim
To examine preferences for oral medication attributes among participants with early and advanced type 2 diabetes mellitus (T2DM) in the UK using a discrete choice experiment (DCE).
Methods
A web‐based DCE was administered where participants indicated which medication they preferred from two different hypothetical oral anti‐diabetic (OAD) medication profiles, each composed of differing levels of seven attributes (efficacy, hypoglycaemic events, weight change, gastrointestinal/nausea side effects, urinary tract infection and genital infection, blood pressure and cardiovascular risk) for 20 sets of pair‐wise comparisons. A random effects multinomial logit regression model was used to estimate the preference weight (PW) for each of the attribute levels, and the relative importance (RI) of each attribute was calculated. Analyses were conducted for the overall sample and for medication and gender subgroups.
Results
The final sample included 100 participants with a mean age of 62.9 (SD 11.1) years and comparable numbers of participants of each gender (51% male, 49% female). The majority of the participants were White‐British (92%). The total PW and corresponding RI were highest for four of the seven attributes: hypoglycaemic events (PW = 1.98; RI = 24.7%), weight change (PW = 1.65; RI = 20.6%), gastrointestinal/nausea side effects (PW = 1.49; RI = 18.6%) and efficacy (PW = 1.44; RI = 18.0%). The RI values differed for some attributes across gender and number of current T2DM medication subgroups.
Conclusion
The results suggest that hypoglycaemia, weight change, gastrointestinal side effects and efficacy are of primary importance to patients in their OAD preferences in T2DM. These four attributes comprised over 80% of the RI.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>23464623</pmid><doi>10.1111/dom.12091</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-8902 |
| ispartof | Diabetes, obesity & metabolism, 2013-09, Vol.15 (9), p.802-809 |
| issn | 1462-8902 1463-1326 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1427002930 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Administration, Oral Adult Blood pressure Cardiovascular diseases Cardiovascular Diseases - chemically induced Cardiovascular Diseases - psychology Choice Behavior Decision Making Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - psychology discrete choice experiment Female Gastrointestinal Diseases - chemically induced Gastrointestinal Diseases - psychology Gender Humans Hypoglycemia Hypoglycemia - chemically induced Hypoglycemia - psychology Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Internet Logistic Models Male Medical research Medication Adherence Middle Aged Nausea Patient Preference Pilot Projects Risk Factors Side effects Studies Surveys and Questionnaires type 2 diabetes United Kingdom - epidemiology Urinary tract Weight Weight Gain - drug effects Weight Loss - drug effects |
| title | Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T19%3A13%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preferences%20for%20medication%20attributes%20among%20patients%20with%20type%202%20diabetes%20mellitus%20in%20the%20UK&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=Gelhorn,%20H.%20L.&rft.date=2013-09&rft.volume=15&rft.issue=9&rft.spage=802&rft.epage=809&rft.pages=802-809&rft.issn=1462-8902&rft.eissn=1463-1326&rft.coden=DOMEF6&rft_id=info:doi/10.1111/dom.12091&rft_dat=%3Cproquest_cross%3E3027474991%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1411992515&rft_id=info:pmid/23464623&rfr_iscdi=true |